<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39404935</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-7403</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Pituitary</Title><ISOAbbreviation>Pituitary</ISOAbbreviation></Journal><ArticleTitle>Hypophysitis in COVID-19: a systematic review.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11102-024-01462-4</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This systematic review aims to collect and examine recent research findings regarding hypophysitis in COVID-19 patients.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We conducted a comprehensive literature review in English on the topic "Hypophysitis in COVID-19," using the MEDLINE (PubMed) database in July 2024. The selected articles were systematically tabulated and we have assessed in this review patient demographics, symptom presentation, imaging results, diagnosis, clinical management, and outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Seven reported cases of post-COVID-19 hypophysitis were identified, comprising 4 (57%) females and 3 (43%) males, with a median age of 37 years. The interval between COVID-19 infection symptoms and the onset of hypophysitis ranged from 2 to 3 weeks. Initial symptoms included frontal headache in 4 (57%) cases and polyuria and polydipsia in 3 (43%) cases. Anterior or posterior hypopituitarism was observed in 6 (85%) patients. Radiological findings varied: 2 (28.5%) cases showed panhypophysitis, 3 (43%) cases exhibited gland enlargement with homogeneous contrast enhancement on magnetic resonance imaging (MRI), 1 case involved the loss of the posterior pituitary bright spot, and 1 case involved pituitary apoplexy/enlargement of the gland and infundibulum. No pituitary biopsies were performed. Four (57%) patients received glucocorticoid (GC) treatment. Long-term follow-up was documented in only one case, a 16-year-old female followed for 2 years reporting complete clinical and radiological resolution.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Although rare, hypophysitis related to COVID-19 is documented in the literature exhibiting distinct characteristics such as a homogeneous gender prevalence, an average age of onset around 35 years, and primary symptoms of headache, polyuria, and polydipsia which are indicative of angiotensin-vasopressin deficiency. This is in contrast with primary autoimmune hypophysitis characterized by a female prevalence and typical symptoms with headache and visual impairment. Longer-term follow-up of these patients is needed to better understand the potential lasting impact on pituitary function and radiological improvement. Future research should also explore the presence of anti-pituitary antibodies and the other possible pathophysiological mechanisms potentially involved in these cases.</AbstractText><CopyrightInformation>© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Menotti</LastName><ForeName>Sara</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3256-3206</Identifier><AffiliationInfo><Affiliation>Institute of Endocrine and Metabolic Sciences, San Raffaele Vita-Salute University and IRCCS San Raffaele Hospital, Via Olgettina 60, 20132, Milan, Italy. menotti.sara@hsr.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>di Filippo</LastName><ForeName>Luigi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Endocrine and Metabolic Sciences, San Raffaele Vita-Salute University and IRCCS San Raffaele Hospital, Via Olgettina 60, 20132, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terenzi</LastName><ForeName>Umberto</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Institute of Endocrine and Metabolic Sciences, San Raffaele Vita-Salute University and IRCCS San Raffaele Hospital, Via Olgettina 60, 20132, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiloiro</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Pituitary Unit, Department of Endocrinology and Diabetes, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Translational Medicine and Surgery, Sacred Heart Catholic University, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Marinis</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Pituitary Unit, Department of Endocrinology and Diabetes, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Translational Medicine and Surgery, Sacred Heart Catholic University, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pituitary</MedlineTA><NlmUniqueID>9814578</NlmUniqueID><ISSNLinking>1386-341X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Angiotensin-vasopressin deficiency</Keyword><Keyword MajorTopicYN="N">Autoimmune</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Hypophysitis</Keyword><Keyword MajorTopicYN="N">Hypothalamus</Keyword><Keyword MajorTopicYN="N">Pituitary</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>11</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39404935</ArticleId><ArticleId IdType="doi">10.1007/s11102-024-01462-4</ArticleId><ArticleId IdType="pii">10.1007/s11102-024-01462-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Capatina C, Poiana C, Fleseriu M (2023) Pituitary and SARS CoV-2: an unremitting conundrum. Best Pract Res Clin Endocrinol Metab 37:101752. https://doi.org/10.1016/j.beem.2023.101752</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.beem.2023.101752</ArticleId><ArticleId IdType="pubmed">36878774</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Kleine-Weber H, Schroeder S et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181:271–280e8. https://doi.org/10.1016/j.cell.2020.02.052</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId><ArticleId IdType="pmc">7102627</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M-Y, Li L, Zhang Y, Wang X-S (2020) Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty 9:45. https://doi.org/10.1186/s40249-020-00662-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40249-020-00662-x</ArticleId><ArticleId IdType="pubmed">32345362</ArticleId><ArticleId IdType="pmc">7186534</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazakou P, Paschou SA, Psaltopoulou T et al (2021) Early and late endocrine complications of COVID-19. Endocr Connect 10:R229–R239. https://doi.org/10.1530/EC-21-0184</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/EC-21-0184</ArticleId><ArticleId IdType="pubmed">34424853</ArticleId><ArticleId IdType="pmc">8494407</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke SA, Abbara A, Dhillo WS (2022) Impact of COVID-19 on the endocrine system: a mini-review. Endocrinology 163. https://doi.org/10.1210/endocr/bqab203</Citation></Reference><Reference><Citation>Mirza SA, Sheikh AAE, Barbera M et al (2022) COVID-19 and the Endocrine System: a review of the current information and misinformation. Infect Dis Rep 14:184–197. https://doi.org/10.3390/idr14020023</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/idr14020023</ArticleId><ArticleId IdType="pubmed">35314653</ArticleId><ArticleId IdType="pmc">8938795</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Filippo L, Formenti AM, Rovere-Querini P et al (2020) Hypocalcemia is highly prevalent and predicts hospitalization in patients with COVID-19. Endocrine 68:475–478. https://doi.org/10.1007/s12020-020-02383-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12020-020-02383-5</ArticleId><ArticleId IdType="pubmed">32533508</ArticleId><ArticleId IdType="pmc">7292572</ArticleId></ArticleIdList></Reference><Reference><Citation>di Filippo L, Allora A, Locatelli M et al (2021) Hypocalcemia in COVID-19 is associated with low vitamin D levels and impaired compensatory PTH response. Endocrine 74:219–225. https://doi.org/10.1007/s12020-021-02882-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12020-021-02882-z</ArticleId><ArticleId IdType="pubmed">34586582</ArticleId><ArticleId IdType="pmc">8480127</ArticleId></ArticleIdList></Reference><Reference><Citation>di Filippo L, Frara S, Giustina A (2021) The emerging osteo-metabolic phenotype of COVID-19: clinical and pathophysiological aspects. Nat Rev Endocrinol 17:445–446. https://doi.org/10.1038/s41574-021-00516-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41574-021-00516-y</ArticleId><ArticleId IdType="pubmed">34079100</ArticleId><ArticleId IdType="pmc">8170860</ArticleId></ArticleIdList></Reference><Reference><Citation>di Filippo L, Doga M, Frara S, Giustina A (2022) Hypocalcemia in COVID-19: prevalence, clinical significance and therapeutic implications. Rev Endocr Metab Disord 23:299–308. https://doi.org/10.1007/s11154-021-09655-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11154-021-09655-z</ArticleId><ArticleId IdType="pubmed">33846867</ArticleId></ArticleIdList></Reference><Reference><Citation>di Filippo L, Frara S, Doga M, Giustina A (2022) The osteo-metabolic phenotype of COVID-19: an update. Endocrine 78:247–254. https://doi.org/10.1007/s12020-022-03135-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12020-022-03135-3</ArticleId><ArticleId IdType="pubmed">35857271</ArticleId><ArticleId IdType="pmc">9297261</ArticleId></ArticleIdList></Reference><Reference><Citation>Frara S, Allora A, Castellino L et al (2021) COVID-19 and the pituitary. Pituitary 24:465–481. https://doi.org/10.1007/s11102-021-01148-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11102-021-01148-1</ArticleId><ArticleId IdType="pubmed">33939057</ArticleId><ArticleId IdType="pmc">8089131</ArticleId></ArticleIdList></Reference><Reference><Citation>Frara S, Loli P, Allora A et al (2022) COVID-19 and hypopituitarism. Rev Endocr Metab Disord 23:215–231. https://doi.org/10.1007/s11154-021-09672-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11154-021-09672-y</ArticleId><ArticleId IdType="pubmed">34387832</ArticleId></ArticleIdList></Reference><Reference><Citation>Finsterer J, Scorza FA (2023) The pituitary gland in SARS-CoV-2 infections, vaccinations, and post-COVID syndrome. Clinics 78:100157. https://doi.org/10.1016/j.clinsp.2022.100157</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinsp.2022.100157</ArticleId><ArticleId IdType="pubmed">36681069</ArticleId></ArticleIdList></Reference><Reference><Citation>Taieb A, Mounira EE (2022) Pilot findings on SARS-CoV-2 Vaccine-Induced Pituitary diseases: a Mini Review from diagnosis to pathophysiology. Vaccines (Basel) 10:2004. https://doi.org/10.3390/vaccines10122004</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10122004</ArticleId><ArticleId IdType="pubmed">36560413</ArticleId></ArticleIdList></Reference><Reference><Citation>Menotti S, Giampietro A, Raia S et al (2023) Unveiling the etiopathogenic spectrum of hypophysitis: a narrative review. J Pers Med 13. https://doi.org/10.3390/jpm13081210</Citation></Reference><Reference><Citation>Langlois F, Varlamov EV, Fleseriu M (2022) Hypophysitis, the growing spectrum of a Rare Pituitary Disease. J Clin Endocrinol Metab 107:10–28. https://doi.org/10.1210/clinem/dgab672</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/clinem/dgab672</ArticleId><ArticleId IdType="pubmed">34528683</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawanduzy CA, Winkler-Schwartz A, Couldwell WT (2023) Hypophysitis: defining histopathologic variants and a review of emerging clinical causative entities. Int J Mol Sci 24:5917. https://doi.org/10.3390/ijms24065917</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24065917</ArticleId><ArticleId IdType="pubmed">36982990</ArticleId><ArticleId IdType="pmc">10057821</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiloiro S, Tartaglione T, Angelini F et al (2017) An overview of diagnosis of primary autoimmune hypophysitis in a prospective single-center experience. Neuroendocrinology 104:280–290. https://doi.org/10.1159/000446544</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000446544</ArticleId><ArticleId IdType="pubmed">27165294</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiloiro S, Capoluongo ED, Tartaglione T et al (2019) The changing clinical spectrum of Hypophysitis. Trends Endocrinol Metabolism 30:590–602. https://doi.org/10.1016/j.tem.2019.06.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2019.06.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Ach T, El Euch M (2022) The need to shed light on potential insidious SARS-CoV-2 post-vaccination pituitary lesions. Therapies. https://doi.org/10.1016/j.therap.2022.11.012</Citation></Reference><Reference><Citation>Poma AM, Proietti A, Macerola E et al (2022) Suppression of Pituitary hormone genes in subjects who died from COVID-19 independently of Virus Detection in the Gland. J Clin Endocrinol Metab 107:2243–2253. https://doi.org/10.1210/clinem/dgac312</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/clinem/dgac312</ArticleId><ArticleId IdType="pubmed">35567590</ArticleId></ArticleIdList></Reference><Reference><Citation>Leow MK-S, Kwek DS-K, Ng AW-K et al (2005) Hypocortisolism in survivors of severe acute respiratory syndrome (SARS). Clin Endocrinol (Oxf) 63:197–202. https://doi.org/10.1111/j.1365-2265.2005.02325.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2265.2005.02325.x</ArticleId><ArticleId IdType="pubmed">16060914</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerrouki D, Assarrar I, Rami I et al (2024) Coronavirus as a trigger of lymphocytic hypophysitis in an adolescent girl: an exceptional case report. Int J Surg Case Rep 115:109218. https://doi.org/10.1016/j.ijscr.2023.109218</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijscr.2023.109218</ArticleId><ArticleId IdType="pubmed">38199020</ArticleId><ArticleId IdType="pmc">10824777</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanczkowski W, Beuschlein F, Bornstein SR (2022) Is there a role for the adrenal glands in long COVID? Nat Rev Endocrinol 18:451–452. https://doi.org/10.1038/s41574-022-00700-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41574-022-00700-8</ArticleId><ArticleId IdType="pubmed">35637413</ArticleId><ArticleId IdType="pmc">9150041</ArticleId></ArticleIdList></Reference><Reference><Citation>Han T, Kang J, Li G et al (2020) Analysis of 2019-nCoV receptor ACE2 expression in different tissues and its significance study. Ann Transl Med 8:1077–1077. https://doi.org/10.21037/atm-20-4281</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm-20-4281</ArticleId><ArticleId IdType="pubmed">33145296</ArticleId><ArticleId IdType="pmc">7576005</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu WT, Zhou F, Xie WQ et al (2021) A potential impact of SARS-CoV-2 on pituitary glands and pituitary neuroendocrine tumors. Endocrine 72:340–348. https://doi.org/10.1007/s12020-021-02697-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12020-021-02697-y</ArticleId><ArticleId IdType="pubmed">33786714</ArticleId><ArticleId IdType="pmc">8009460</ArticleId></ArticleIdList></Reference><Reference><Citation>Conde Cardona G, Quintana Pájaro LD, Quintero Marzola ID et al (2020) Neurotropism of SARS-CoV 2: mechanisms and manifestations. J Neurol Sci 412:116824. https://doi.org/10.1016/j.jns.2020.116824</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2020.116824</ArticleId><ArticleId IdType="pubmed">32299010</ArticleId><ArticleId IdType="pmc">7141641</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao L, Jin H, Wang M et al (2020) Neurologic manifestations of hospitalized patients with Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol 77:683. https://doi.org/10.1001/jamaneurol.2020.1127</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.1127</ArticleId><ArticleId IdType="pubmed">32275288</ArticleId></ArticleIdList></Reference><Reference><Citation>Chigr F, Merzouki M, Najimi M (2020) Autonomic Brain centers and Pathophysiology of COVID-19. ACS Chem Neurosci 11:1520–1522. https://doi.org/10.1021/acschemneuro.0c00265</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.0c00265</ArticleId><ArticleId IdType="pubmed">32427468</ArticleId></ArticleIdList></Reference><Reference><Citation>Pal R (2020) COVID-19, hypothalamo-pituitary-adrenal axis and clinical implications. Endocrine 68:251–252. https://doi.org/10.1007/s12020-020-02325-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12020-020-02325-1</ArticleId><ArticleId IdType="pubmed">32346813</ArticleId><ArticleId IdType="pmc">7186765</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg M, Gopalakrishnan M, Yadav P, Misra S (2020) Endocrine involvement in COVID-19: mechanisms, clinical features, and implications for care. Indian J Endocrinol Metab 24:381. https://doi.org/10.4103/ijem.IJEM_440_20</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijem.IJEM_440_20</ArticleId><ArticleId IdType="pubmed">33489841</ArticleId><ArticleId IdType="pmc">7810055</ArticleId></ArticleIdList></Reference><Reference><Citation>Sogkas G, Atschekzei F, Adriawan IR et al (2021) Cellular and molecular mechanisms breaking immune tolerance in inborn errors of immunity. Cell Mol Immunol 18:1122–1140. https://doi.org/10.1038/s41423-020-00626-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-00626-z</ArticleId><ArticleId IdType="pubmed">33795850</ArticleId><ArticleId IdType="pmc">8015752</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff MC, Ramonell RP, Nguyen DC et al (2020) Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nat Immunol 21:1506–1516. https://doi.org/10.1038/s41590-020-00814-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-00814-z</ArticleId><ArticleId IdType="pubmed">33028979</ArticleId><ArticleId IdType="pmc">7739702</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin C, Zhou L, Hu Z et al (2020) Dysregulation of Immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 71:762–768. https://doi.org/10.1093/cid/ciaa248</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa248</ArticleId><ArticleId IdType="pubmed">32161940</ArticleId></ArticleIdList></Reference><Reference><Citation>Heaney AP, Sumerel B, Rajalingam R et al (2015) HLA markers DQ8 and DR53 are Associated with lymphocytic hypophysitis and May Aid in Differential diagnosis. J Clin Endocrinol Metab 100:4092–4097. https://doi.org/10.1210/jc.2015-2702</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2015-2702</ArticleId><ArticleId IdType="pubmed">26317559</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiloiro S, Capoluongo ED, Tartaglione T et al (2018) Human leucocyte antigens coeliac haplotypes and primary autoimmune hypophysitis in caucasian patients. Clin Endocrinol (Oxf) 88:692–699. https://doi.org/10.1111/cen.13566</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cen.13566</ArticleId><ArticleId IdType="pubmed">29418012</ArticleId></ArticleIdList></Reference><Reference><Citation>Megiorni F, Mora B, Bonamico M et al (2009) HLA-DQ and risk gradient for celiac disease. Hum Immunol 70:55–59. https://doi.org/10.1016/j.humimm.2008.10.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humimm.2008.10.018</ArticleId><ArticleId IdType="pubmed">19027045</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupi I, Zhang J, Gutenberg A et al (2011) From Pituitary expansion to empty Sella: Disease Progression in a mouse model of Autoimmune Hypophysitis. Endocrinology 152:4190–4198. https://doi.org/10.1210/en.2011-1004</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/en.2011-1004</ArticleId><ArticleId IdType="pubmed">21862619</ArticleId><ArticleId IdType="pmc">3198994</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiloiro S, Giampietro A, Bianchi A et al (2017) Diagnosis of endocrine disease: primary empty sella: a comprehensive review. Eur J Endocrinol 177:R275–R285. https://doi.org/10.1530/EJE-17-0505</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/EJE-17-0505</ArticleId><ArticleId IdType="pubmed">28780516</ArticleId></ArticleIdList></Reference><Reference><Citation>Naran J, Can AS (2023) Lymphocytic hypophysitis. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island</Citation></Reference><Reference><Citation>Racca G, D’Agnano S, Fasano N, Gianotti L (2022) Pituitary apoplexy with transition to acute hypophysitis in a patient with SARS-CoV-2 pneumonia. JCEM Case Rep 1. https://doi.org/10.1210/jcemcr/luac010</Citation></Reference><Reference><Citation>Lizzi M, Aricò M, Carlone G et al (2022) Central Diabetes Insipidus: another rare complication of SARS-CoV-2 infection in children? Pediatr Infect Disease J 41:e448–e448. https://doi.org/10.1097/INF.0000000000003632</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000003632</ArticleId></ArticleIdList></Reference><Reference><Citation>Misgar RA, Rasool A, Wani AI, Bashir MI (2021) Central diabetes insipidus (Infundibuloneuro hypophysitis): a late complication of COVID-19 infection. J Endocrinol Invest 44:2855–2856. https://doi.org/10.1007/s40618-021-01627-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40618-021-01627-z</ArticleId><ArticleId IdType="pubmed">34215999</ArticleId><ArticleId IdType="pmc">8253675</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonglait P, Naik R, Raizada N (2021) Hypophysitis after COVID-19 infection. Indian J Endocrinol Metab 25:255. https://doi.org/10.4103/ijem.ijem_329_21</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijem.ijem_329_21</ArticleId><ArticleId IdType="pubmed">34760685</ArticleId><ArticleId IdType="pmc">8547401</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorbova NYu, Vladimirova VP, Rozhinskaya LY, Belaya ZY (2022) Hypophysitis and reversible hypopituitarism developed after COVID-19 infection — a clinical case report. Probl Endocrinol 68:50–56. https://doi.org/10.14341/probl12896</Citation><ArticleIdList><ArticleId IdType="doi">10.14341/probl12896</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi M, Gunawardena S, Goenka A et al (2022) Post COVID-19 lymphocytic hypophysitis: a rare presentation. Child Neurol Open 9:2329048X2211030. https://doi.org/10.1177/2329048X221103051</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2329048X221103051</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiloiro S, Giampietro A, Bianchi A, De Marinis L (2016) Clinical management of teratoma, a rare hypothalamic-pituitary neoplasia. Endocrine 53(3):636–642. https://doi.org/10.1007/s12020-015-0814-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12020-015-0814-4</ArticleId><ArticleId IdType="pubmed">26701679</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh AB, Javaid MA, Sheikh AAE, Shekhar R (2021) Central adrenal insufficiency and diabetes insipidus as potential endocrine manifestations of COVID-19 infection: a case report. Pan Afr Med J 38:222. https://doi.org/10.11604/pamj.2021.38.222.28243</Citation><ArticleIdList><ArticleId IdType="doi">10.11604/pamj.2021.38.222.28243</ArticleId><ArticleId IdType="pubmed">34046127</ArticleId><ArticleId IdType="pmc">8140727</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh AB, Javed N, Sheikh AAE et al (2021) Diabetes insipidus and concomitant myocarditis: a late sequelae of COVID-19 infection. J Investig Med High Impact Case Rep 9:2324709621999954. https://doi.org/10.1177/2324709621999954</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2324709621999954</ArticleId><ArticleId IdType="pubmed">33686899</ArticleId><ArticleId IdType="pmc">7952841</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajevac H, Bachan M, Khan Z (2020) Diabetes insipidus as a symptom of covid-19 infection: case report. Chest 158:A2576. https://doi.org/10.1016/j.chest.2020.09.172</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2020.09.172</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartaglione T, Chiloiro S, Laino ME et al (2018) Neuro-radiological features can predict hypopituitarism in primary autoimmune hypophysitis. Pituitary 21:414–424. https://doi.org/10.1007/s11102-018-0892-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11102-018-0892-4</ArticleId><ArticleId IdType="pubmed">29752700</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi MN, Whitelaw BC, Carroll PV (2018) Mechanisms in endocrinology: Hypophysitis: diagnosis and treatment. Eur J Endocrinol 179:R151–R163. https://doi.org/10.1530/EJE-17-0009</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/EJE-17-0009</ArticleId><ArticleId IdType="pubmed">29880706</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y, Zhou G, Du J et al (2024) Hypophysitis after COVID-19 vaccination in a patient with Rathke’s cleft cyst: a case report. Hum Vaccin Immunother. https://doi.org/10.1080/21645515.2023.2297455</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2023.2297455</ArticleId><ArticleId IdType="pubmed">39171541</ArticleId><ArticleId IdType="pmc">11346555</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuo T, Okubo K, Mifune H, Imao T (2023) Bilateral Optic Neuritis and Hypophysitis with Diabetes Insipidus 1 Month after COVID-19 mRNA vaccine: Case Report and Literature Review. J Investig Med High Impact Case Rep. https://doi.org/10.1177/23247096231186046</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/23247096231186046</ArticleId><ArticleId IdType="pubmed">37737575</ArticleId><ArticleId IdType="pmc">10517617</ArticleId></ArticleIdList></Reference><Reference><Citation>Faje A (2016) Hypophysitis: evaluation and management. Clin Diabetes Endocrinol 2:15. https://doi.org/10.1186/s40842-016-0034-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40842-016-0034-8</ArticleId><ArticleId IdType="pubmed">28702249</ArticleId><ArticleId IdType="pmc">5471685</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubbi S, Hannah-Shmouni F, Verbalis JG, Koch CA (2019) Hypophysitis: an update on the novel forms, diagnosis and management of disorders of pituitary inflammation. Best Pract Res Clin Endocrinol Metab 33:101371. https://doi.org/10.1016/j.beem.2019.101371</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.beem.2019.101371</ArticleId><ArticleId IdType="pubmed">31866206</ArticleId><ArticleId IdType="pmc">7078033</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnappa B, Shah R, Sarathi V et al (2022) Early Pulse glucocorticoid therapy and improved hormonal outcomes in primary hypophysitis. Neuroendocrinology 112:186–195. https://doi.org/10.1159/000516006</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000516006</ArticleId><ArticleId IdType="pubmed">33744880</ArticleId></ArticleIdList></Reference><Reference><Citation>Imga NN, Yildirim AE, Baser OO, Berker D (2019) Clinical and hormonal characteristics of patients with different types of hypophysitis: a single-center experience. Arch Endocrinol Metab 63:47–52. https://doi.org/10.20945/2359-3997000000102</Citation><ArticleIdList><ArticleId IdType="doi">10.20945/2359-3997000000102</ArticleId><ArticleId IdType="pubmed">30864631</ArticleId><ArticleId IdType="pmc">10118843</ArticleId></ArticleIdList></Reference><Reference><Citation>Amereller F, Küppers A-M, Schilbach K et al (2021) Clinical characteristics of primary hypophysitis – a single-Centre Series of 60 cases. Exp Clin Endocrinol Diabetes 129:234–240. https://doi.org/10.1055/a-1163-7304</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1163-7304</ArticleId><ArticleId IdType="pubmed">32770534</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerbone M, Visser J, Bulwer C et al (2021) Management of children and young people with idiopathic pituitary stalk thickening, central diabetes insipidus, or both: a national clinical practice consensus guideline. Lancet Child Adolesc Health 5:662–676. https://doi.org/10.1016/S2352-4642(21)00088-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(21)00088-2</ArticleId><ArticleId IdType="pubmed">34214482</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleseriu M, Hashim IA, Karavitaki N et al (2016) Hormonal replacement in hypopituitarism in adults: an endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 101:3888–3921. https://doi.org/10.1210/jc.2016-2118</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2016-2118</ArticleId><ArticleId IdType="pubmed">27736313</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomkins M, Lawless S, Martin-Grace J et al (2022) Diagnosis and management of Central Diabetes Insipidus in adults. J Clin Endocrinol Metab 107:2701–2715. https://doi.org/10.1210/clinem/dgac381</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/clinem/dgac381</ArticleId><ArticleId IdType="pubmed">35771962</ArticleId><ArticleId IdType="pmc">9516129</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein SR, Ramelli SC, Grazioli A et al (2022) SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature 612:758–763. https://doi.org/10.1038/s41586-022-05542-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05542-y</ArticleId><ArticleId IdType="pubmed">36517603</ArticleId><ArticleId IdType="pmc">9749650</ArticleId></ArticleIdList></Reference><Reference><Citation>Artamonova IN, Petrova NA, Lyubimova NA et al (2022) Case report: COVID-19-associated ROHHAD-like syndrome. Front Pediatr 10. https://doi.org/10.3389/fped.2022.854367</Citation></Reference><Reference><Citation>Verrienti M, Marino Picciola V, Ambrosio MR, Zatelli MC (2024) Pituitary and COVID-19 vaccination: a systematic review. Pituitary. https://doi.org/10.1007/s11102-024-01402-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11102-024-01402-2</ArticleId><ArticleId IdType="pubmed">38761322</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Z, Zhu H, Wang X et al (2020) Adjuvants for coronavirus vaccines. Front Immunol 11. https://doi.org/10.3389/fimmu.2020.589833</Citation></Reference><Reference><Citation>Baig AM, Khaleeq A, Ali U, Syeda H (2020) Evidence of the COVID-19 Virus Targeting the CNS: tissue distribution, host–Virus Interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci 11:995–998. https://doi.org/10.1021/acschemneuro.0c00122</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.0c00122</ArticleId><ArticleId IdType="pubmed">32167747</ArticleId></ArticleIdList></Reference><Reference><Citation>Ankireddypalli AR, Chow LS, Radulescu A et al (2022) A case of Hypophysitis Associated with SARS-CoV-2 vaccination. AACE Clin Case Rep 8:204–209. https://doi.org/10.1016/j.aace.2022.06.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.aace.2022.06.001</ArticleId><ArticleId IdType="pubmed">35754921</ArticleId><ArticleId IdType="pmc">9212943</ArticleId></ArticleIdList></Reference><Reference><Citation>Murvelashvili N, Tessnow A (2021) A case of Hypophysitis following immunization with the mRNA-1273 SARS-CoV-2 vaccine. J Investig Med High Impact Case Rep 9:232470962110433. https://doi.org/10.1177/23247096211043386</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/23247096211043386</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzeo P, Ceccato F, Manara R et al (2024) Transient central diabetes insipidus (Arginine Vasopressin Deficiency) following SARS-CoV-2 vaccination: a case report and literature review. Endocr Metab Immune Disord Drug Targets. https://doi.org/10.2174/0118715303286560231124115052</Citation></Reference><Reference><Citation>Partenope C, Pedranzini Q, Petri A et al (2023) AVP deficiency (central diabetes insipidus) following immunization with anti-COVID-19 BNT162b2 Comirnaty vaccine in adolescents: a case report. Front Endocrinol (Lausanne). https://doi.org/10.3389/fendo.2023.1166953</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2023.1166953</ArticleId><ArticleId IdType="pubmed">37143723</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishay A, Shacham EC (2023) Central diabetes insipidus: a late sequela of BNT162b2 SARS-CoV-2 mRNA vaccine? BMC Endocr Disord 23:47. https://doi.org/10.1186/s12902-023-01296-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12902-023-01296-4</ArticleId><ArticleId IdType="pubmed">36810011</ArticleId><ArticleId IdType="pmc">9945387</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyo C, Kobayashi T, Iwama S et al (2024) A case of hypophysitis after COVID-19 vaccination with a detection of anti-pituitary antibody, with review of literature. Endocr J EJ 24–0061. https://doi.org/10.1507/endocrj.EJ24-0061</Citation></Reference><Reference><Citation>Ach T, Kammoun F, Fekih H, El et al (2022) Central diabetes insipidus revealing a hypophysitis induced by SARS-CoV-2 vaccine. Therapies. https://doi.org/10.1016/j.therap.2022.09.007</Citation></Reference><Reference><Citation>Bouça B, Roldão M, Bogalho P et al (2022) Central Diabetes Insipidus following immunization with BNT162b2 mRNA COVID-19 vaccine: a Case Report. Front Endocrinol (Lausanne). https://doi.org/10.3389/fendo.2022.889074</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2022.889074</ArticleId><ArticleId IdType="pubmed">35600593</ArticleId></ArticleIdList></Reference><Reference><Citation>Morita S, Tsuji T, Kishimoto S et al (2022) Isolated ACTH deficiency following immunization with the BNT162b2 SARS-CoV-2 vaccine: a case report. BMC Endocr Disord 22:185. https://doi.org/10.1186/s12902-022-01095-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12902-022-01095-3</ArticleId><ArticleId IdType="pubmed">35854260</ArticleId><ArticleId IdType="pmc">9297640</ArticleId></ArticleIdList></Reference><Reference><Citation>Puig-Domingo M, Marazuela M, Yildiz BO, Giustina A (2021) COVID-19 and endocrine and metabolic diseases. An updated statement from the European Society of Endocrinology. Endocrine 72:301–316. https://doi.org/10.1007/s12020-021-02734-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12020-021-02734-w</ArticleId><ArticleId IdType="pubmed">33963516</ArticleId><ArticleId IdType="pmc">8105151</ArticleId></ArticleIdList></Reference><Reference><Citation>Marazuela M, Giustina A, Puig-Domingo M (2020) Endocrine and metabolic aspects of the COVID-19 pandemic. Rev Endocr Metab Disord 21:495–507. https://doi.org/10.1007/s11154-020-09569-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11154-020-09569-2</ArticleId><ArticleId IdType="pubmed">32643004</ArticleId><ArticleId IdType="pmc">7343578</ArticleId></ArticleIdList></Reference><Reference><Citation>Giustina A (2021) Hypovitaminosis D and the endocrine phenotype of COVID-19. Endocrine 72:1–11. https://doi.org/10.1007/s12020-021-02671-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12020-021-02671-8</ArticleId><ArticleId IdType="pubmed">33738708</ArticleId><ArticleId IdType="pmc">7972333</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan S, Karim M, Gupta V et al (2023) A Comprehensive Review of COVID-19–Associated endocrine manifestations. South Med J 116:350–354. https://doi.org/10.14423/SMJ.0000000000001542</Citation><ArticleIdList><ArticleId IdType="doi">10.14423/SMJ.0000000000001542</ArticleId><ArticleId IdType="pubmed">37011583</ArticleId><ArticleId IdType="pmc">10044587</ArticleId></ArticleIdList></Reference><Reference><Citation>Feghali K, Atallah J, Norman C (2021) Manifestations of thyroid disease post COVID-19 illness: report of Hashimoto Thyroiditis, Graves’ disease, and subacute thyroiditis. J Clin Transl Endocrinol Case Rep 22:100094. https://doi.org/10.1016/j.jecr.2021.100094</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jecr.2021.100094</ArticleId><ArticleId IdType="pubmed">34462717</ArticleId><ArticleId IdType="pmc">8387132</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanzolla G, Marcocci C, Marinò M (2021) Graves’ disease and Graves’ orbitopathy following COVID-19. J Endocrinol Invest 44:2011–2012. https://doi.org/10.1007/s40618-021-01576-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40618-021-01576-7</ArticleId><ArticleId IdType="pubmed">33964007</ArticleId><ArticleId IdType="pmc">8106371</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiménez-Blanco S, Pla-Peris B, Marazuela M (2021) COVID-19: a cause of recurrent Graves’ hyperthyroidism? J Endocrinol Invest 44:387–388. https://doi.org/10.1007/s40618-020-01440-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40618-020-01440-0</ArticleId><ArticleId IdType="pubmed">33025554</ArticleId></ArticleIdList></Reference><Reference><Citation>Mateu-Salat M, Urgell E, Chico A (2020) SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves’ disease after COVID-19. J Endocrinol Invest 43:1527–1528. https://doi.org/10.1007/s40618-020-01366-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40618-020-01366-7</ArticleId><ArticleId IdType="pubmed">32686042</ArticleId><ArticleId IdType="pmc">7368923</ArticleId></ArticleIdList></Reference><Reference><Citation>Muniangi-Muhitu H, Akalestou E, Salem V et al (2020) Covid-19 and diabetes: a complex bidirectional relationship. Front Endocrinol (Lausanne). https://doi.org/10.3389/fendo.2020.582936</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2020.582936</ArticleId><ArticleId IdType="pubmed">33133024</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Al-Aly Z (2022) Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol 10:311–321. https://doi.org/10.1016/S2213-8587(22)00044-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(22)00044-4</ArticleId><ArticleId IdType="pubmed">35325624</ArticleId><ArticleId IdType="pmc">8937253</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahmati M, Keshvari M, Mirnasuri S et al (2022) The global impact of COVID-19 pandemic on the incidence of pediatric new‐onset type 1 diabetes and ketoacidosis: a systematic review and meta‐analysis. J Med Virol 94:5112–5127. https://doi.org/10.1002/jmv.27996</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27996</ArticleId><ArticleId IdType="pubmed">35831242</ArticleId><ArticleId IdType="pmc">9350204</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng SM, Woodger K, Regan F et al (2020) Presentation of newly diagnosed type 1 diabetes in children and young people during COVID-19: a national UK survey. BMJ Paediatr Open 4:e000884. https://doi.org/10.1136/bmjpo-2020-000884</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjpo-2020-000884</ArticleId><ArticleId IdType="pubmed">34192183</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellastella G, Maiorino MI, Esposito K (2020) Endocrine complications of COVID-19: what happens to the thyroid and adrenal glands? J Endocrinol Invest 43:1169–1170. https://doi.org/10.1007/s40618-020-01311-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40618-020-01311-8</ArticleId><ArticleId IdType="pubmed">32488724</ArticleId><ArticleId IdType="pmc">7265876</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheatland R (2004) Molecular mimicry of ACTH in SARS – implications for corticosteroid treatment and prophylaxis. Med Hypotheses 63:855–862. https://doi.org/10.1016/j.mehy.2004.04.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2004.04.009</ArticleId><ArticleId IdType="pubmed">15488660</ArticleId><ArticleId IdType="pmc">7126000</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoste L, Van Paemel R, Haerynck F (2021) Multisystem inflammatory syndrome in children related to COVID-19: a systematic review. Eur J Pediatr 180:2019–2034. https://doi.org/10.1007/s00431-021-03993-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-021-03993-5</ArticleId><ArticleId IdType="pubmed">33599835</ArticleId><ArticleId IdType="pmc">7890544</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui X, Zhao Z, Zhang T et al (2021) A systematic review and meta-analysis of children with coronavirus disease 2019 (COVID‐19). J Med Virol 93:1057–1069. https://doi.org/10.1002/jmv.26398</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26398</ArticleId><ArticleId IdType="pubmed">32761898</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolopoulou GB, Maltezou HC (2022) COVID-19 in children: where do we stand? Arch Med Res 53:1–8. https://doi.org/10.1016/j.arcmed.2021.07.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2021.07.002</ArticleId><ArticleId IdType="pubmed">34311990</ArticleId></ArticleIdList></Reference><Reference><Citation>Biousse V, D’Anglejan-Chatillon J, Massiou H, Bousser M-G (1994) Head Pain in non-traumatic carotid artery dissection: a Series of 65 patients. Cephalalgia 14:33–36. https://doi.org/10.1046/j.1468-2982.1994.1401033.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1468-2982.1994.1401033.x</ArticleId><ArticleId IdType="pubmed">8200023</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter SM, Laderman M, Polk P (2021) Pediatric Headache attributed to infection. Semin Pediatr Neurol 40:100923. https://doi.org/10.1016/j.spen.2021.100923</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.spen.2021.100923</ArticleId><ArticleId IdType="pubmed">34749918</ArticleId></ArticleIdList></Reference><Reference><Citation>Christ-Crain M, Hoorn EJ, Sherlock M et al (2020) Endocrinology in the time of covid-19: management of diabetes insipidus and hyponatraemia. Eur J Endocrinol 183:G9–G15. https://doi.org/10.1530/EJE-20-0338</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/EJE-20-0338</ArticleId><ArticleId IdType="pubmed">32380474</ArticleId><ArticleId IdType="pmc">7938013</ArticleId></ArticleIdList></Reference><Reference><Citation>Yavari A, Sharifan Z, Larijani B, Mosadegh Khah A (2022) Central diabetes insipidus secondary to COVID-19 infection: a case report. BMC Endocr Disord 22:134. https://doi.org/10.1186/s12902-022-01048-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12902-022-01048-w</ArticleId><ArticleId IdType="pubmed">35590312</ArticleId><ArticleId IdType="pmc">9117597</ArticleId></ArticleIdList></Reference><Reference><Citation>Pérez-Torres D, Díaz-Rodríguez C, Armentia-Medina A (2022) Anti-ACTH antibodies in critically ill Covid-19 patients: a potential immune evasion mechanism of SARS-CoV-2. Med Intensiva (English Edition) 46:472–474. https://doi.org/10.1016/j.medine.2021.09.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medine.2021.09.001</ArticleId></ArticleIdList></Reference><Reference><Citation>De Bellis A, Bizzarro A, Bellastella A (2005) Pituitary antibodies and lymphocytic hypophysitis. Best Pract Res Clin Endocrinol Metab 19:67–84. https://doi.org/10.1016/j.beem.2004.11.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.beem.2004.11.007</ArticleId><ArticleId IdType="pubmed">15826923</ArticleId></ArticleIdList></Reference><Reference><Citation>De Bellis A, Bizzarro A, Perrino S et al (2005) Characterization of antipituitary antibodies targeting pituitary hormone-secreting cells in idiopathic growth hormone deficiency and autoimmune endocrine diseases. Clin Endocrinol (Oxf) 63:45–49. https://doi.org/10.1111/j.1365-2265.2005.02296.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2265.2005.02296.x</ArticleId><ArticleId IdType="pubmed">15963060</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiloiro S, Capoluongo ED, Angelini F et al (2022) Autoantibody reactivity profile of primary autoimmune hypophysitis patients: preliminary results. Endocrine 76:224–227. https://doi.org/10.1007/s12020-021-02937-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12020-021-02937-1</ArticleId><ArticleId IdType="pubmed">34797510</ArticleId></ArticleIdList></Reference><Reference><Citation>Das L, Dutta P (2023) Approach to the patient: a Case with an unusual cause of Hypopituitarism. J Clin Endocrinol Metab 108:1488–1504. https://doi.org/10.1210/clinem/dgac747</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/clinem/dgac747</ArticleId><ArticleId IdType="pubmed">36573291</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonen MS, De Bellis A, Durcan E et al (2022) Assessment of neuroendocrine changes and hypothalamo-pituitary autoimmunity in patients with COVID-19. Horm Metab Res 54:153–161. https://doi.org/10.1055/a-1764-1260</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1764-1260</ArticleId><ArticleId IdType="pubmed">35276740</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiloiro S, Tartaglione T, Capoluongo ED et al (2018) Hypophysitis outcome and factors Predicting responsiveness to glucocorticoid therapy: a prospective and double-arm study. J Clin Endocrinol Metab 103:3877–3889. https://doi.org/10.1210/jc.2018-01021</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2018-01021</ArticleId><ArticleId IdType="pubmed">30085134</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleseriu M, Buchfelder M, Cetas JS et al (2020) Pituitary society guidance: pituitary disease management and patient care recommendations during the COVID-19 pandemic—an international perspective. Pituitary 23:327–337. https://doi.org/10.1007/s11102-020-01059-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11102-020-01059-7</ArticleId><ArticleId IdType="pubmed">32556793</ArticleId><ArticleId IdType="pmc">7300368</ArticleId></ArticleIdList></Reference><Reference><Citation>Arlt W, Baldeweg SE, Pearce SHS, Simpson HL (2020) ENDOCRINOLOGY IN THE TIME OF COVID-19: management of adrenal insufficiency. Eur J Endocrinol 183:G25–G32. https://doi.org/10.1530/EJE-20-0361</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/EJE-20-0361</ArticleId><ArticleId IdType="pubmed">32379699</ArticleId><ArticleId IdType="pmc">7938015</ArticleId></ArticleIdList></Reference><Reference><Citation>Refardt J, Atila C, Christ-Crain M (2023) New insights on diagnosis and treatment of AVP deficiency. Rev Endocr Metab Disord. https://doi.org/10.1007/s11154-023-09862-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11154-023-09862-w</ArticleId><ArticleId IdType="pubmed">38087160</ArticleId><ArticleId IdType="pmc">11162367</ArticleId></ArticleIdList></Reference><Reference><Citation>di Filippo L, Franzese V, Santoro S, Doga M, Giustina A (2024) Long COVID and pituitary dysfunctions: a bidirectional relationship? Pituitary. https://doi.org/10.1007/s11102-024-01442-8</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>